Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 3;9(2):003164.
doi: 10.12890/2022_003164. eCollection 2022.

Pityriasis Rosea Induced by COVID-19 Vaccination

Elina Khattab  1 , Eirini Christaki  2 , Constantinos Pitsios  1
Affiliations

Pityriasis Rosea Induced by COVID-19 Vaccination

Elina Khattab et al. Eur J Case Rep Intern Med. .

Abstract

It is increasingly recognized that SARS-CoV-2 infection and COVID-19 vaccines have been associated with skin disorders, including pityriasis rosea. It has been reported that pityriasis rosea has been triggered by several vaccines, as a rare side-effect. We present two cases of COVID-19 vaccine-induced pityriasis rosea. Skin lesions appeared in a 49-year-old female 8 days after the first dose of the BNT162b2 mRNA vaccine and in a 53-year-old male 7 days after the second dose of the same vaccine. The exanthem was self-limited in both patients over a period of a month.

Learning points: Physicians should be aware that pityriasis rosea is a rare side-effect of COVID-19 vaccination.Pityriasis rosea is self-limiting and no medical treatment is usually required.

Keywords: COVID-19; SARS-CoV-2; pityriasis rosea; vaccination.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interests: The authors declare there are no competing interests.

Figures

Figure 1
Figure 1
Herald patch in the right hypochondrium followed by typical oval-shaped secondary plaques
Figure 2
Figure 2
Pityriasis rosea lesions on the upper extremities
See this image and copyright information in PMC

References

    1. Busto-Leis JM, Servera-Negre G, Mayor-Ibarguren A, Sendagorta-Cudós E, Feito-Rodríguez M, Nuño-González A, et al. Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance. J Eur Acad Dermatol Venereol. 2021;35(8):e489–e491. - PMC - PubMed
    1. Johansen M, Chisolm SS, Aspey LD, Brahmbhatt M. Pityriasis rosea in otherwise asymptomatic confirmed COVID-19-positive patients: a report of 2 cases. JAAD Case Rep. 2021;7:93–94. - PMC - PubMed
    1. Welsh E, Cardenas-de la Garza JA, Cuellar-Barboza A, Franco-Marquez R, Arvizu-Rivera RI. SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19. Br J Dermatol. 2021;184(6):1194–1195. - PMC - PubMed
    1. Carballido Vázquez AM, Morgado B. Pityriasis rosea-like eruption after Pfizer–BioNTech COVID-19 vaccination. Br J Dermatol. 2021;185(2):e34. - PMC - PubMed
    1. Cyrenne BM, Al-Mohammedi F, DeKoven JG, Alhusayen R. Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021;35(9):e546–e548. - PMC - PubMed

LinkOut - more resources